MedPath

FDA Lifts Partial Clinical Hold on Vigil Neuroscience's VG-3927 Phase I Trial, Expands to Alzheimer's Patients

• The FDA has lifted the partial clinical hold on Vigil Neuroscience's Phase I trial of VG-3927, a treatment for neurodegenerative diseases, following a complete response from the company. • Interim data from the trial indicated VG-3927's safety, tolerability, and potential for once-daily dosing, alongside a sustained decline in soluble TREM2 levels in cerebrospinal fluid. • The Phase I trial has expanded to include Alzheimer's disease patients, including those with TREM2 or other disease-related genetic variations, to assess biomarker response. • Vigil Neuroscience plans to release complete Phase I data, including results from the Alzheimer's patient cohort, in the first quarter of next year.

The FDA has lifted the partial clinical hold on Vigil Neuroscience’s Phase I trial of VG-3927, a novel treatment for neurodegenerative diseases linked to microglial dysfunction, particularly Alzheimer’s disease. The decision follows a complete response submitted by Vigil Neuroscience to the regulator.

Promising Early Data

Interim findings from the single- and multiple-ascending dose study of VG-3927 in healthy subjects, shared in July, demonstrated that the drug is suitable for further clinical exploration based on safety and tolerability data from six SAD and two MAD cohorts. The pharmacokinetic profile supported the potential for once-daily dosing. VG-3927 also showed promising signs of efficacy, including a sustained decline in soluble TREM2 levels in the cerebrospinal fluid (CSF), providing clinical evidence of target engagement. An increase in osteopontin/secreted phosphoprotein 1 (SPP1) was also observed after repeated doses of the treatment.

Expansion to Alzheimer's Patients

The ongoing Phase I trial has now expanded to include patients suffering from Alzheimer’s disease, some of whom have TREM2 or other disease-related genetic variations. This cohort will help assess VG-3927’s biomarker response after a single dose.

Future Plans

Vigil Neuroscience aims to release the complete Phase I data, including results from the Alzheimer’s patient cohort, in the first quarter of next year.

About VG-3927

VG-3927 is a small molecule TREM2 agonist being developed to address neurodegenerative diseases linked to microglial dysfunction, initially focusing on treating Alzheimer’s disease.

Executive Perspective

Vigil Neuroscience chief medical officer Petra Kaufmann said, “We are pleased with the resolution of the partial clinical hold, a decision that was supported by non-clinical and clinical data from our ongoing Phase I trial. While the partial clinical hold did not delay the clinical development of VG-3927, the option to increase the exposure limit provides us the best opportunity to explore the full pharmacology of VG-3927 as a potentially novel, next-generation therapy for those living with Alzheimer’s disease.”
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cerevance's CVN293 Shows Promise in Phase I Trial for Neurodegenerative Diseases

Cerevance's CVN293 demonstrated favorable safety and brain penetration in a Phase I trial involving healthy volunteers, supporting its potential for treating neurodegenerative conditions.
The study showed that CVN293 was generally well-tolerated across all tested doses, with no serious adverse events reported, indicating a promising safety profile.

FDA Updates: Clinical Hold on Rapport's RAP-219 for DPNP, Phase 2 Trial for Mivelsiran in CAA, and Review of Ataluren Resubmission

The FDA has placed a clinical hold on Rapport Therapeutics' RAP-219 IND application for diabetic peripheral neuropathic pain (DPNP) due to protocol design concerns.
A phase 2 trial (cAPPricorn-1) will evaluate Alnylam's mivelsiran, an RNAi therapeutic targeting APP, for cerebral amyloid angiopathy (CAA) in a 200-patient global study.

Vesper Bio's VES001 Shows Promise in Phase 1 Trial for Frontotemporal Dementia

Vesper Bio announced positive results from its Phase 1 clinical trial of VES001, an oral drug for frontotemporal dementia (FTD) linked to GRN mutations.
The trial demonstrated excellent safety and tolerability of VES001 in healthy volunteers, with normalization of progranulin levels observed.

FDA Lifts Clinical Hold on Avidity's Delpacibart Etedesiran (AOC 1001) for Myotonic Dystrophy Type 1

The FDA has lifted the partial clinical hold on Avidity Biosciences' delpacibart etedesiran (del-desiran/AOC 1001) for myotonic dystrophy type 1 (DM1).
The clinical hold was initiated in 2022 following a serious adverse event in a patient during the Phase I/II MARINA trial.

NervGen Nears Enrollment Completion in Spinal Cord Injury Trial of NVG-291

NervGen Pharma is approaching target enrollment in the chronic cohort of its Phase 1b/2a trial for NVG-291 in spinal cord injury (SCI).
The trial evaluates NVG-291's efficacy in chronic and subacute cervical SCI patients using clinical, electrophysiological, and MRI measures.

FDA Lifts Partial Clinical Hold on Azenosertib Trials in Advanced Solid Tumors

The FDA has lifted the partial clinical hold on trials evaluating azenosertib, a WEE1 inhibitor, in patients with advanced solid tumors, allowing studies to resume enrollment.
The hold was initiated in June 2024 due to two deaths from presumed sepsis in the DENALI trial, but the FDA has now reviewed and approved Zentalis Pharmaceuticals' response package.

Vesper Bio's VES001 Shows Promise in Phase I Trial for Frontotemporal Dementia

Vesper Bio's VES001 demonstrated a favorable safety and tolerability profile in a Phase I trial involving 78 healthy subjects.
The study confirmed that VES001 effectively distributes to plasma and the central nervous system after oral administration.

FDA Grants Priority Review to Vimseltinib for Tenosynovial Giant Cell Tumor

The FDA has granted priority review to vimseltinib for treating tenosynovial giant cell tumor (TGCT), setting a PDUFA goal date of February 17, 2025.
Vimseltinib, a CSF1R inhibitor, demonstrated a 40% overall response rate in the MOTION phase 3 trial, significantly higher than placebo (0%).

FDA Lifts Clinical Hold on 4D Molecular Therapeutics' Fabry Disease Gene Therapy Trial

The FDA has removed the clinical hold on the phase 1/2 INGLAXA trial for 4D Molecular Therapeutics' 4D-310, a gene therapy for Fabry disease, allowing patient enrollment to continue with plans for an update in 2025. The trial was previously halted due to serious adverse events, which have since resolved.

FDA Lifts Partial Clinical Hold on RVU120 Trial in AML and MDS

The FDA has lifted a partial clinical hold on the phase 1b trial of RVU120 (SEL120) in relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
The trial will resume enrollment with a revised protocol, starting with a 75-mg dose of RVU120 every other day, following recommendations from the FDA to improve patient safety.

Reference News

[1]
FDA lifts partial clinical hold on Vigil Neuroscience's Phase I VG-3927 trial
clinicaltrialsarena.com · Sep 18, 2024

FDA lifts partial clinical hold on Vigil Neuroscience's Phase I trial of VG-3927, a TREM2 agonist for neurodegenerative ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy